BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.

Zacks Investment Research • 18 hours ago

BioMarin Pharmaceutical Q2 Earnings Call Highlights

BioMarin Pharmaceutical NASDAQ: BMRN reported second-quarter 2026 revenue of nearly $1 billion, up 20% from a year earlier, as growth across its rare-disease portfolio and the recently completed Amicus acquisition supported results. The company raised its full-year revenue, VOXZOGO revenue and non-GAAP diluted earnings-per-share guidance, though it did not provide updated ranges during the call.

MarketBeat • Aug 6, 2026

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO®, and Non-GAAP Diluted Earnings Per Share (EPS) Addition of GALAFOLD® and POMBILITI® + OPFOLDA®, with Cost Synergies, Expected to Accelerate Revenue Growth, Non-GAAP Diluted EPS Accretion, Non-GAAP Operating Margin Expansion, and Operating Cash Flow through the Mid-2030s Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.

PRNewsWire • Aug 6, 2026

BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.2 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.44 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Aug 6, 2026

BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET

SAN RAFAEL, Calif., July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m.

PRNewsWire • Jul 30, 2026

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Jul 27, 2026

BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome

ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition Collaboration combines BioMarin's leadership in genetic medicines with n-Lorem's pioneering antisense expertise Investigational antisense oligonucleotide (ASO) aims to address the underlying genetic cause of this serious neurodevelopmental condition SAN RAFAEL, Calif. and SAN DIEGO, July 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and n-Lorem Foundation, a nonprofit organization, today announced a strategic collaboration and global exclusive license agreement to develop a first-in-disease, antisense oligonucleotide (ASO) medicine for people living with ReNU syndrome, a serious and rare neurodevelopmental condition caused by variants in the RNU4-2 gene.

PRNewsWire • Jul 27, 2026

BioMarin: Commercial Infrastructure Is The Hidden Growth Asset

BioMarin: Commercial Infrastructure Is The Hidden Growth Asset

Seeking Alpha • Jul 22, 2026